Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2024

10-02-2024 | Helicobacter Pylori | Review Article

Helicobacter pylori Eradication Treatment in Older Patients

Authors: Paulius Jonaitis, Juozas Kupcinskas, Javier P. Gisbert, Laimas Jonaitis

Published in: Drugs & Aging | Issue 2/2024

Login to get access

Abstract

Helicobacter pylori is the main etiopathogenetic factor of chronic gastritis, peptic ulcer disease and gastric cancer. The world’s population is shifting towards older people, who have the highest prevalence of H. pylori. Aging-related peculiarities could have an impact on the treatment of H. pylori and there is still a lack of research data in the older population. The aim of this review was to summarize the findings of the most recent information, publications and studies on the issues relating to H. pylori infection in older patients. H. pylori eradication offers gastrointestinal and extra gastrointestinal benefits in older patients. Based on the main guidelines, H. pylori should be eradicated independent of the patient’s age, only reconsidering cases with terminal illness and low life expectancy. Proton pump inhibitors are generally safe and well tolerated. Some antibiotics require dose adjustment only in advanced renal insufficiency and the risk of hepatotoxicity is very low. Special precautions should be taken in patients with polypharmacy and those taking aspirin or non-steroidal anti-inflammatory drugs. In older patients, H. pylori eradication treatment frequently causes only mild and short-term adverse events; however, treatment compliance is usually still very good. H. pylori treatment in older patients does not increase the risk of Clostridium difficile infection. Optimal eradication effectiveness (> 90%) is mostly achieved with bismuth- and non-bismuth-based quadruple therapies. Susceptibility-guided treatment of H. pylori can contribute to increasing the effectiveness of eradication regimens in older adults. To achieve optimal H. pylori eradication effectiveness in older patients, the same guidelines, which are applied to adults, also apply to this population: avoiding repetitive treatment prescriptions, choosing quadruple therapies, prescribing longer treatment duration and administering high-dose proton pump inhibitors twice daily.
Literature
1.
Mitchell E, Walker R. Global ageing: successes, challenges and opportunities. Br J Hosp Med. 2020;81(2):1–9.
2.
3.
4.
Singh S, Bajorek B. Defining, “Elderly” in Clinical Practice Guidelines for Pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.PubMedPubMedCentral
5.
Sieber CC. The elderly patient—who is that? Internist (Berl). 2007;48(11):1190,1192-11901194.PubMed
6.
Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine (Baltimore). 2019;98(30): e16619.PubMed
7.
Liu T. Super-aging and Social Security for the Most Elderly in China. Z Gerontol Geriatr. 2018;51(1):105–12.PubMed
8.
Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115(3):219–24.PubMedPubMedCentral
9.
Senchukova MA, Tomchuk O, Shurygina EI. Helicobacter pylori in gastric cancer: features of infection and their correlations with long-term results of treatment. World J Gastroenterol. 2021;27(37):6290–305.PubMedPubMedCentral
10.
Norwood DA, Montalvan-Sanchez E, Dominguez RL, Morgan DR. Gastric cancer: emerging trends in prevention, diagnosis, and treatment. Gastroenterol Clin N Am. 2022;51(3):501–18.
11.
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J-M, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–62.
12.
Jamkhande PG, Gattani SG, Farhat SA. Helicobacter pylori and cardiovascular complications: a mechanism based review on role of Helicobacter pylori in cardiovascular diseases. Integr Med Res. 2016;5(4):244–9.PubMedPubMedCentral
13.
Kountouras J, Boziki M, Polyzos SA, Katsinelos P, Gavalas E, Zeglinas C, et al. The emerging role of Helicobacter pylori-induced metabolic gastrointestinal dysmotility and neurodegeneration. Curr Mol Med. 2017;17(6):389–404.PubMed
14.
15.
Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553–64.PubMed
16.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.PubMed
17.
Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the seroprevalence of Helicobacter pylori among the Lithuanian medical students over the last 25 years and its relation to dyspeptic symptoms. Medicina. 2021;57(3):254.
18.
19.
Peng C, Hu Y, Ge Z-M, Zou Q-M, Lyu N-H. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med. 2019;5(4):243–51.PubMed
20.
den Hoed CM, Vila AJ, Holster IL, Perez-Perez GI, Blaser MJ, de Jongste JC, et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter. 2011;16(5):405–9.
21.
Kienesberger S, Perez-Perez GI, Olivares AZ, Bardhan P, Sarker SA, Hasan KZ, et al. When is Helicobacter pylori acquired in populations in developing countries? A birth-cohort study in Bangladeshi children. Gut Microbes. 2018;9(3):252–63.PubMedPubMedCentral
22.
Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100(9):2083–209.PubMed
23.
Hu Y, Wan J-H, Li X-Y, Zhu Y, Graham DY, Lu N-H. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773–9.PubMed
24.
Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, et al. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect. 2020;9(1):548–57.PubMedPubMedCentral
25.
Joo Y-E, Park H-K, Myung D-S, Baik G-H, Shin J-E, Seo G-S, et al. Prevalence and Risk factors of atrophic gastritis and intestinal Metaplasia: a Nationwide Multicenter Prospective Study in Korea. Gut Liver. 2013;7(3):303–10.PubMedPubMedCentral
26.
Cizginer S, Ordulu Z, Kadayifci A. Approach to Helicobacter pylori infection in geriatric population. World J Gastrointest Pharmacol Ther. 2014;5(3):139–47.PubMedPubMedCentral
27.
Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori infection in geriatric patients: current situation and treatment regimens. Front Med. 2021;8: 713908.
28.
Jonaitis P, Nyssen OP, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, et al. Comparison of the management of helicobacter pylori infection between the older and younger European Populations. Sci Rep. 2023;13(1):17235.PubMedPubMedCentralADS
29.
Ganda Mall J-P, Östlund-Lagerström L, Lindqvist CM, Algilani S, Rasoal D, Repsilber D, et al. Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress? BMC Geriatr. 2018;18(1):75.PubMedPubMedCentral
30.
Pilotto A, Maggi S, Noale M, Franceschi M, Parisi G, Crepaldi G. Association of upper gastrointestinal symptoms with functional and clinical charateristics in elderly. World J Gastroenterol. 2011;17(25):3020–6.PubMedPubMedCentral
31.
32.
33.
Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J Clin Diagnostic Res JCDR. 2016;10(12):FC40–3.
34.
Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19(1):12–8.PubMed
35.
Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care. 2008;11(5):651–60.PubMed
36.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut. 2015;64(9):1353–67.PubMed
37.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–39.PubMed
38.
Chitapanarux T, Kongkarnka S, Wannasai K, Sripan P. Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: a multivariate, hospital-based, statistical analysis. Cancer Epidemiol. 2023;82: 102309.PubMed
39.
Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PET. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis. 2008;40(5):355–60.PubMed
40.
Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2): e12475.PubMed
41.
Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155(1):67–75.PubMed
42.
Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after helicobacter pylori eradication. J Gastroenterol. 2020;55(3):281–8.PubMed
43.
Wu S-R, Liu Y-H, Shi Y-Q. Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis? Chin Med J (Engl). 2021;134(24):2965–7.PubMed
44.
Hwang Y-J, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication—a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–90.PubMed
45.
Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154-162.e3.PubMed
46.
Khan MY, Aslam A, Mihali AB, Shabbir Rawala M, Dirweesh A, Khan S, et al. Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(6):686–94.PubMed
47.
Chen H-N, Wang Z, Li X, Zhou Z-G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166–75.PubMed
48.
Ng JC, Yeomans ND. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. Med J Aust. 2018;209(7):306–11.PubMed
49.
Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2022;400(10363):1597–606.PubMed
50.
Hellström PM, Benno P, Malfertheiner P. Gastrointestinal bleeding in patients with helicobacter pylori and dual platelet inhibition after myocardial infarction. Lancet Gastroenterol Hepatol. 2021;6(9):684–5.PubMed
51.
Waluga M, Kukla M, Żorniak M, Bacik A, Kotulski R. From the stomach to other organs: Helicobacter pylori and the liver. World J Hepatol. 2015;7(18):2136–46.PubMedPubMedCentral
52.
Yu Y-Y, Tong Y-L, Wu L-Y, Yu X-Y. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022;12(1):19530.PubMedPubMedCentralADS
53.
Lolekha P, Sriphanom T, Vilaichone R-K. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson’s disease patients: a prospective cohort study (HP-PD trial). PLoS ONE. 2021;16(5): e0251042.PubMedPubMedCentral
54.
Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16(2):124–30.PubMed
55.
Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in Goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95.PubMed
56.
Rahmani Y, Mohammadi S, Babanejad M, Rai A, Zalei B, Shahmohammadi A. Association of Helicobacter pylori with presence of myocardial infarction in Iran: a systematic review and meta-analysis. Ethiop J Health Sci. 2017;27(4):433–40.PubMedPubMedCentral
57.
Azarkar Z, Jafarnejad M, Sharifzadeh G. The relationship between Helicobacter pylori infection and myocardial infarction. Casp J Intern Med. 2011;2(2):222–5.
58.
Sharma V, Aggarwal A. Helicobacter pylori: does it add to risk of coronary artery disease. World J Cardiol. 2015;7(1):19–25.PubMedPubMedCentral
59.
60.
Kovesdy CP. Epidemiology of Chronic Kidney Disease: an Update 2022. Kidney Int Suppl. 2022;12(1):7–11.
61.
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96.PubMedPubMedCentral
62.
Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1): e12759.PubMedPubMedCentral
63.
Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31(4):263–82.PubMed
64.
Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.PubMedPubMedCentral
65.
Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273–80.PubMed
66.
Nabeta H, Shinozaki S, Abe Y, Koyanagi R, Nakamichi T, Kobayashi Y, et al. A potassium-competitive acid blocker-based regimen as second-line therapy improves Helicobacter pylori eradication. Digestion. 2020;101(3):332–8.PubMed
67.
Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59(2):153–61.PubMed
68.
Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(12):2217–28.PubMedPubMedCentral
69.
70.
71.
Tsai C-E, Liang C-M, Lee C-H, Kuo Y-H, Wu K-L, Chiu Y-C, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32(8):397–402.PubMed
72.
Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41(2):134–40.PubMed
73.
Sharma NR, Wagle A, Bist M, Panthi B, Pokhrel Dahal R, Rokaya R, et al. Clarithromycin-induced Acute Liver injury in a Patient with Positive Helicobacter pylori: a Case Report and Review of the Literature. Vol. 85, Annals of medicine and surgery (2012). England; 2023. p. 4629–32.
74.
Cheng D-D, He C, Ai H-H, Huang Y, Lu N-H. The possible role of Helicobacter pylori infection in non-alcoholic fatty liver disease. Front Microbiol. 2017;8:743.PubMedPubMedCentral
75.
Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al. Adverse event profile during the treatment of helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–9.PubMed
76.
Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic stewardship for older adults in ambulatory care settings: addressing an unmet challenge. J Am Geriatr Soc. 2020;68(2):244–9.PubMed
77.
Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40(7):997–1004.PubMed
78.
Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, et al. Rates of antimicrobial resistance in helicobacter pylori isolates from clinical trial patients across the US and Europe. Am J Gastroenterol. 2023;118(2):269–75.PubMed
79.
Denkinger CM, Grant AD, Denkinger M, Gautam S, D’Agata EMC. Increased multi-drug resistance among the elderly on admission to the hospital—a 12-year surveillance study. Arch Gerontol Geriatr. 2013;56(1):227–30.PubMed
80.
Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50(7 Suppl):S226–9.PubMed
81.
Gao C, Fan Y-H. Effect and safety of helicobacter pylori eradication treatment based on molecular pathologic antibiotic resistance in chinese elderly people. Infect Drug Resist. 2022;15:3277–86.PubMedPubMedCentral
82.
Durazzo M, Ferro A, Fagoonee S, Staiano MT, Saracco GM, Pellicano R. Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. Panminerva Med. 2021;63(3):332–5.PubMed
83.
Ma T-L, Tai W-C, Loke S-S, Yao C-C, Liang C-M, Chuah S-K. Efficacy and safety of 7-day non-Bismuth concomitant quadruple therapy for first-line Helicobacter pylori eradication in the elderly. Drugs Aging. 2023;40(1):71–9.PubMed
84.
Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, et al. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter. 2006;11(1):52–5.PubMed
85.
Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21(12):1419–24.PubMed
86.
Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.PubMedPubMedCentral
87.
Li W, Zeng S, Yu L-S, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259–71.PubMedPubMedCentral
88.
Cadiou G, Adam M, Caussin M, Landrin I, Mariette N, Capet C, et al. Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs. Fundam Clin Pharmacol. 2012;26(2):307–13.PubMed
89.
Jonaitis P, Jonaitis L, Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr Drug Metab. 2020;21(11): 830–837.
90.
Harmsze AM, de Boer A, Boot H, Deneer VHM, Heringa M, Mol PGM, et al. Interaction Between Clopidogrel and Proton Pump Inhibitors. Ned Tjdschrift voor Geneeskd. 2011;155(28):A2442.
91.
Choi YJ, Kim N, Jang I-J, Cho J-Y, Nam RH, Park JH, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504–11.PubMedPubMedCentral
92.
Scott SA, Owusu Obeng A, Hulot J-S. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.PubMed
93.
Hines LE, Murphy JE. Potentially Harmful Drug-drug Interactions in the Elderly: a Review. Am J Geriatr Pharmacother. 2011;9(6):364–77.PubMed
94.
Soraci L, Cherubini A, Paoletti L, Filippelli G, Luciani F, Laganà P, et al. Safety and tolerability of antimicrobial agents in the older patient. Drugs Aging. 2023;40(6):499–526.PubMedPubMedCentral
95.
Lee SP, Sung I-K, Kim JH, Lee S-Y, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clin Endosc. 2017;50(6):578–84.PubMed
96.
Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol. 2012;27(Suppl 3):8–12.PubMed
97.
Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.PubMedPubMedCentral
98.
O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019;171(8):596–8.PubMedPubMedCentral
99.
Pilotto A, Franceschi M, Maggi S, Addante F, Sancarlo D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging. 2010;27(7):545–58.PubMed
100.
Joo MK. Helicobacter pylori eradication in drug-related peptic ulcer. Korean J Gastroenterol. 2020;76(5):227–31.PubMed
101.
102.
Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med. 2018;18(3):237–41.
103.
Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The positive association between proton pump inhibitors and Clostridium difficile infection. Inov Pharm. 2021;12(1):1–7.
104.
Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K, et al. Proton-pump inhibitor use and the risk of community-associated Clostridium difficile Infection. Clin Infect Dis. 2021;72(12):e1084–9.PubMedPubMedCentral
105.
Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori is not associated with future clostridium difficile infection. Am J Gastroenterol. 2020;115(5):716–22.PubMedPubMedCentral
106.
Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19(42):7476–9.PubMedPubMedCentral
107.
108.
Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. A triple-drug blister-packaged drug with vonoprazan improves first-line eradication of Helicobacter pylori in elderly patients: a retrospective propensity score-matched cohort study. Digestion. 2020;101(5):608–14.PubMed
109.
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united states and europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19.PubMed
110.
Yang Q, He C, Hu Y, Hong J, Zhu Z, Xie Y, et al. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: a prospective, randomized controlled trial. Front Pharmacol. 2023;14:1096103.PubMedPubMedCentral
111.
Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H. pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25(5): e12717.PubMedPubMedCentral
112.
Mestrovic A, Perkovic N, Tonkic A, Sundov Z, Kumric M, Bozic J. Personalized approach in eradication of Helicobacter pylori infection. Antibiot (Basel, Switzerland). 2022;12(1):7.
113.
Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20(29):9912–21.PubMedPubMedCentral
114.
Nyssen OP, Espada M, Gisbert JP. Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis. Front Microbiol. 2022;13:913436.PubMedPubMedCentral
115.
Kuo C-H, Lu C-Y, Shih H-Y, Liu C-J, Wu M-C, Hu H-M, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029–36.PubMedPubMedCentral
116.
Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, et al. Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis. Front Pharmacol. 2021;12: 759249.PubMedPubMedCentral
117.
Mestre A, Sathiya Narayanan R, Rivas D, John J, Abdulqader MA, Khanna T, et al. Role of probiotics in the management of Helicobacter pylori. Cureus. 2022;14(6): e26463.PubMedPubMedCentral
Metadata
Title
Helicobacter pylori Eradication Treatment in Older Patients
Authors
Paulius Jonaitis
Juozas Kupcinskas
Javier P. Gisbert
Laimas Jonaitis
Publication date
10-02-2024
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2024
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-023-01090-w

Other articles of this Issue 2/2024

Drugs & Aging 2/2024 Go to the issue

Original Research Article

Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker–Loop Diuretic Prescribing Cascade

Therapy in Practice

Diagnosis and pharmacological management of microscopic colitis in geriatric care

Original Research Article

Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older Patients

Original Research Article

Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients

Original Research Article

Potentially Inappropriate Psychotropic Drugs in Nursing Homes: An Italian Observational Study

Leading Article

The Current Landscape of Pharmacotherapies for Sarcopenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits